Atsena Reports LIGHTHOUSE data at ARVO

Atsena Therapeutics announced positive clinical data results from Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). The data were presented at the 2025 Association for Research in Vision and Ophthalmology meeting in Salt Lake City, Utah.

May 1, 2025
3 min

Retinal Physician

Original Source(s)

Retinal Physician

Atsena Reports LIGHTHOUSE data at ARVO

May 1, 2025

Related Content

Retinal Physician

Racing Toward Efficient AI Workflows

At the Focus A-Eye Summit, in the session “Lessons from Formula One: Optimizing Clinical Workflow with AI,” experts examined how artificial intelligence can streamline and accelerate ophthalmic clinical workflows.

by Devinder Chauhan, MD, FRCOphth, FRANZCO
May 1, 2026
2 min

Bmc Ophthalmology

Distinctive Liver Function in Individuals with High Myopia: Links to Myopic Macular Degeneration

by Yujun Pei, Jiaqi Meng, Wenwen He, Keke Zhang, Dongling Guo, Yi Lu, Xiangjia Zhu
November 28, 2025

The Ophthalmologist

Eric Souied Joins SeaBeLife

French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee

March 9, 2026
2 min